Onkologisch-Gastroenterologische Schwerpunktpraxis Innere Medizin GbR

Research site

Germany Virchowstrasse 10c, 78224 Singen (Hohentwiel), Germany

2 trials recruiting
Hormone receptor positive HER2 negative breast cancer · Hormone receptor positive breast cancer · Breast cancer female
Adult patients

About Specializations

Onkologisch-Gastroenterologische Schwerpunktpraxis Innere Medizin GbR in Singen (Hohentwiel), Germany specialises in clinical trials of conditions such as Hormone receptor positive HER2 negative breast cancer, Hormone receptor positive breast cancer, Breast cancer female, and other specialisations. This site conducts important research.

Main research areas of the site

Advanced Hormone‑Receptor Positive, HER2‑Negative Breast Cancer

The site focuses on neoplasm research, particularly on metastatic HR‑positive, HER2‑negative breast cancer, evaluating new treatment strategies to improve survival and quality of life.

Comprehensive analysis of ribociclib efficacy and resistance mechanisms
Evaluation of CDK4/6 inhibitor discontinuation after prolonged disease control
Assessment of progression‑free and overall survival outcomes at 12 months
Integration of endocrine therapy for long‑term disease stabilization

Located at Virchowstrasse 10c, Singen, the Gastroenterology Oncology department of Onkologisch‑Gastroenterologische Schwerpunktpraxis Innere Medizin GbR conducts two investigator‑led trials to advance therapeutic options for patients with advanced breast cancer.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Virchowstrasse 10c78224 Singen (Hohentwiel)Germany

Open in maps ↗

Recruiting now: 2 trials
Conditions studied: 3

More sites in Singen (Hohentwiel)Germany

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

2 clinical trials

Hormone receptor positive breast cancer+1

Recruiting

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo

Study on Stopping CDK4/6 Inhibitors in Patients with Metastatic HR Positive, HER2 Negative Breast Cancer Using Abemaciclib, Letrozole, and Fulvestrant

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Abemaciclib
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Hormone receptor positive breast cancer+2

Recruiting

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Study on Ribociclib and Drug Combination for Patients with Advanced HER2-Negative, Hormone Receptor Positive Breast Cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Anastrozole
Sponsor:Institut Für Frauengesundheit GmbH

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites